Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells. Phase II trial shows efficacy in PsA, further trials to come. #ABS0894 #ACR20 @RheumNow https://t.co/gzf7epPyNd https://t.co/ArLlCyzLxR
Links:
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriat…
http://ow.ly/8urw50Cavwd
07-11-2020